Please login to the form below

Not currently logged in
Email:
Password:

Sun Pharma buys Taro Pharmaceuticals to increase US reach

Sun Pharmaceutical Industries has agreed to buy Israel-based generics firm, Taro Pharmaceutical Industries, for USD 230m in cash and an extra USD 224m (USD 454m) to refinance Taro's debt

India's largest pharmaceutical company, Sun Pharmaceutical Industries (Sun), has agreed to buy Israel-based generics firm, Taro Pharmaceutical Industries, for USD 230m in cash and an extra USD 224m (USD 454m) to refinance Taro's debt, according to a company statement release on 21 May.

Taro reported on 20 March that it would report a substantial loss in FY06, which would put it in breach of conditions on bank loans. The Taro acquisition will help Sun to expand its marketing network in the US, without having to establish a separate entity in the region. Sun anticipates an increase in the demand for generic drugs as healthcare costs increase and blockbuster drugs lose patent protection.

The acquisition will provide Sun with an extra 170 scientists and drugs for childhood illnesses and skin diseases. The company's shares rose INR 36.8 (USD 0.91), or 3.6 per cent, to INR 1,050 (USD 25.90) on the Mumbai Stock Exchange, gaining a total of 6.9 per cent so far in 2007.

Sun says it will use its profits and the proceeds from the USD 350m sale of bonds convertible into shares to fund the acquisition, which is subject approval by Taro shareholders and a regulatory review.

According to local media reports, Franklin Advisers and Templeton, who together hold a nine per cent share in Taro, filed a request for a temporary injunction against the deal on 19 May, adding that it could harm minority shareholders. The motion was heard on 21 May and a ruling is due soon.

Sun's USD 7.75-a-share offer values Taro at 27 per cent higher than its closing price of USD 6.10 on 18 May. Taro shares have lost 86 per cent of their value over the past three years.

Sun reported robust financials for the year ending 31 March 2007, with net sales were INR 21.3bn (USD 528.8m), a 30 per cent increase from INR 16.4bn (USD 406.9m) in the year ending 31 March 2006. Sun's international business grew 39 per cent, while EBITDA margin increased to 32.7 per cent from 30.8 per cent in the previous financial year, despite a 51 per cent increase in R&D revenue expense. Net profit was INR 7.7bn (USD 192.1m), an increase of 35 per cent, while Sun's net margin at 37 per cent for the year ending 31 March 2007 was higher than the previous year.

23rd May 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics